Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25493988 | 0.87 | ENPP2 (0.38) | ENPP2TSHRCA1CA2ESR2 | |
| SCHEMBL1668130 | 0.85 | ENPP2 (0.37) | ENPP2TSHRCA1CA2ESR2 | |
| SCHEMBL29950680 | 0.85 | DYRK1A (0.41) | ENPP2TSHRCA1CA2ESR2 | |
| SCHEMBL29741613 | 0.85 | TSHR (0.54) | ENPP2TSHRCA1CA2ESR2 | |
| SCHEMBL29950793 | 0.85 | ENPP2 (0.37) | ENPP2TSHRCA1CA2ESR2 | |
| SCHEMBL17629928 | 0.80 | ALDH1A1 (0.40) | TSHRCA1CA2HTTNOTUM | |
| SCHEMBL8849581 | 0.80 | ESR2 (0.49) | TSHRCA1CA2ESR2PDK2 | |
| SCHEMBL4335270 | 0.80 | ENPP2 (0.46) | ENPP2TSHRKDM4EALDH1A1 | |
| SCHEMBL29952058 | 0.80 | ENPP2 (0.46) | ENPP2TSHRKDM4EALDH1A1 | |
| SCHEMBL29468918 | 0.73 | TSHR (0.50) | ENPP2TSHRCA1CA2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3597645-B1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-110734418-B | Condensed-cyclic compound, composition including the same, and organic light-emitting device | 三星电子株式会社 | 2024-01-26 | — | — | CN | disclosed |
| US-11053228-B2 | Condensed cyclic compound, composition including the condensed cyclic compound, and organic light-emitting device including the condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-07-06 | — | — | US | disclosed |
| CN-110734418-A | Fused ring compound, and composition and organic light-emitting device including same | 三星电子株式会社 | 2020-01-31 | — | — | CN | disclosed |
| US-20200031812-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | SAMSUNG SDI CO., LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1049662-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053228-B2 | Condensed cyclic compound, composition including the condensed cyclic compound, and organic light-emitting device including the condensed cyclic compound | CCNL2, ARL1, CRY1 | ENPP2 3229/4885TSHR 3598/4885CA1 2403/4885 |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | ENPP2 3126/4885TSHR 2994/4885CA1 1768/4885 |
| US-20200031812-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | CCNL2, ARL1, CRY1 | ENPP2 3229/4885TSHR 3598/4885CA1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.